Ocular involvement in Behçet's disease: First 5-year-results for visual development after treatment with interferon alfa-2a;Augenbeteiligung bei morbus Behçet: Erste 5-jahres-ergebnisse zur visusentwucklung nach therapie mit interferon alfa-2a

Ophthalmologe

Volumn 101, Issue 2, 2004, Pages 129-134

  Deuter, C M E ^a   Kotter I ^a   Gunaydin I ^a   Zierhut, M ^a   Stubiger N ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Beh et's disease; Immunosuppressive treatment; Interferon alfa 2a; Visual prognosis

Indexed keywords

ALPHA2A INTERFERON; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; EYE DISEASE; FOLLOW UP; HUMAN; PROGNOSIS; REMISSION; RETINA VASCULITIS; TREATMENT OUTCOME; UVEITIS; VISION; VISUAL ACUITY;

EID: 10744225028     PISSN: 0941293X     EISSN: 14330423     Source Type: Journal    
DOI: 10.1007/s00347-003-0927-7     Document Type: Article

References (18)

1. BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 70:589-592
2. Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D (1998) Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med 243:367-372
3. International Study Group for Behçet's disease (1990) Criteria for diagnosis of Behçet's disease. Lancet 335:1078-1080
4. Kötter I, Aepinus C, Graepler F et al (2001) HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha. Ann Rheum Dis 60:83-86
5. Kötter I, Dürk H, Saal JG, Eckstein A, Zierhut M, Fierlbeck G (1996) Morbus Behçet. Epidemiologie, Verlauf, therapeutische Optionen. Dtsch Med Wschr 121:382-388
6. Kötter I, Dürk H, Saal J, Fierlbeck G, Pleyer U, Zierhut M (1996) Therapy of Behçet's disease. Ger J Ophthalmol 5:92-97
7. 2a: a pilot study. Br J Ophthalmol 82:488-494
8. Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423-431
9. Mamo JG (1970) The rate of visual loss in Behçet's disease. Arch Ophthalmol 84:451-452
10. Mishima S, Masuda K, Izawa Y, Mochizuke M, Namba K (1979) Behçet's disease in Japan: ophthalmological aspects. Trans Am Ophthalmol Soc 76:225-279
11. Palestine AG, Austin HA, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB (1986) Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314:1293-1298
12. Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G (1985) Prognosis in Behçet's disease. Ann Ophthalmol 17:20-25
13. Stübiger N, Kötter I, Deuter C, Zierhut M (2001) Morbus Behçet: Uveitis-Therapie mit Interferon alfa-2a - prospektive klinische (Pilot-)Studie an 33 Patienten. Klin Monatsbl Augenheilkd 218:768-773
14. Stübiger N, Kötter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 84:1437-1438
15. Süllü Y, Öge I, Erkan D, Aritürk N, Mohajeri F (1998) Cyclosporin-A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand 76:96-99
16. Wechsler B, Bodaghi B, Huong DL et al (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8:293-301
17. Whitcup SM, Salvo EC, Nussenblatt RB (1994) Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 118:39-45
18. Zierhut M, Saal J, Pleyer U, Kötter I, Dürk H, Fierlbeck G (1995) Behçet's disease: epidemiology and eye manifestations in German and Mediterranian patients. Ger J Ophthalmol 4:246-251